29. Non-Alcoholic Fatty Liver Disease

  1. John WD McDonald Professor of Medicine2,
  2. Andrew K Burroughs Professor of Hepatology Consultant Physician/Hepatologist3,
  3. Brian G Feagan Professor of Medicine2 and
  4. M Brian Fennerty Professor of Medicine4
  1. Christopher P Day

Published Online: 22 JUL 2010

DOI: 10.1002/9781444314403.ch29

Evidence-Based Gastroenterology and Hepatology, Third Edition

Evidence-Based Gastroenterology and Hepatology, Third Edition

How to Cite

Day, C. P. (2010) Non-Alcoholic Fatty Liver Disease, in Evidence-Based Gastroenterology and Hepatology, Third Edition (eds J. W. McDonald, A. K. Burroughs, B. G. Feagan and M. B. Fennerty), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444314403.ch29

Editor Information

  1. 2

    Robarts Clinical Trials, Robarts Research Unit, University of Western Ontario, London, Ontario, Canada

  2. 3

    The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, and University College London, London, UK

  3. 4

    Oregon Health and Science University, Division of Gastroenterology and Hepatology, Portland, Oregon, USA

Author Information

  1. Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, UK

Publication History

  1. Published Online: 22 JUL 2010
  2. Published Print: 10 SEP 2010

ISBN Information

Print ISBN: 9781405181938

Online ISBN: 9781444314403

SEARCH

Keywords:

  • Natural history of NAFLD;
  • Disease associations with NAFLD;
  • Overall management strategy for NAFLD;
  • Treatments directed at components of the metabolic syndrome;
  • Treatments directed at the liver;
  • Non-alcoholic fatty liver disease (NAFLD);
  • non-alcoholic steatohepatitis (NASH);
  • Polycystic ovary syndrome [PCOS];
  • alanine transaminase (ALT);
  • gamma glutamyl transpeptidase (GGT)

Summary

This chapter contains sections titled:

  • Introduction

  • Epidemiology

  • Natural history of NAFLD

  • Susceptibility

  • Disease associations with NAFLD

  • Clinical presentation

  • Investigation

  • Overall management strategy for NAFLD

  • Treatments directed at components of the metabolic syndrome

  • Treatments directed at the liver

  • References